DIMO Healthcare introduces ZEISS SLT revolutionising glaucoma treatment in Sri Lanka

DIMO, a leading diversified conglomerate in Sri Lanka, is pleased to announce the successful introduction of ZEISS Selective Laser Trabeculoplasty (SLT) technology through its esteemed healthcare arm, DIMO Healthcare. 
This groundbreaking laser treatment has revolutionised the management of glaucoma by effectively controlling the internal pressure of the eye through a single procedure, significantly reducing the need for daily medication in glaucoma patients. 

The installation of the first ZEISS SLT at Mount Lotus Hospital marks a significant milestone in the field of ophthalmology in Sri Lanka. DIMO Healthcare, as the authorised local agent for ZEISS, remains committed to bringing advanced solutions to the country’s healthcare landscape. This treatment approach aligns with the recommendations of the National Institute for Health and Care Excellence (NICE) in the UK, which identifies SLT as the primary therapy for individuals newly diagnosed with chronic open-angle glaucoma. 

Glaucoma, a prevalent eye condition, poses a global concern. ZEISS SLT offers a significant breakthrough by minimising medication reliance for glaucoma patients, enhancing convenience and optimising treatment outcomes. Traditional glaucoma management often necessitates multiple daily medication administrations. However, the introduction of ZEISS SLT presents patients with a more streamlined and efficient treatment experience.   

The innovative ZEISS SLT technology not only benefits but also empowers ophthalmologists and glaucoma specialists. By enabling a comprehensive review of patient data prior to examination and treatment, facilitating SLT procedures and providing centralised access to diagnostic data and laser treatment reports, ZEISS SLT streamlines the entire treatment process. These capabilities, available at the VISULAS workstation or remotely within the clinic, enhance efficiency and enable precise pre-and post-operative evaluation. 

DIMO Healthcare Chief Operating Officer Priyantha Dissanayake expressed his enthusiasm, stating, “DIMO Healthcare takes immense pride in introducing cutting-edge technologies in collaboration with our esteemed partners. From the revolutionary OCT technology in 2003, enabling visualisation of internal eye structures, to the wide-angle fundus camera introduced in 2019 for hassle-free fundus examination, our commitment to innovation remains unwavering. We are driven by our purpose of fuelling the dreams and aspirations of our communities while actively contributing to building a healthier nation.”